CAR T‐cell therapy of solid tumors. Issue 4 (17th January 2017)

• Record Type: Journal Article
• Authors: Yong, Carmen S M; Dardalhon, Valerie; Devaud, Christel; Taylor, Naomi; Darcy, Phillip K; Kershaw, Michael H
• Is Part Of: Immunology and cell biology. Volume 95:Issue 4(2017)
• Page Start: 356
• Page End: 363
• Publication Date: 2017-01-17
• Subjects: Immunology -- Periodicals; Cytology -- Periodicals; 616.079
• DOI: 10.1038/icb.2016.128
• Languages: English
• ISSNs: 0818-9641

Abstract

Abstract : The potential for immunotherapy as a treatment option for cancer is clear from remarkable responses of some leukemia patients to adoptive cell transfer using autologous T cells genetically modified to express chimeric antigen receptors (CARs). However, the vast majority of cancers, in particular the more common solid cancers, such as those of the breast, colon and lung, fail to respond significantly to infusions of CAR T cells. Solid cancers present some formidable barriers to adoptive cell transfer, including suppression of T‐cell function and inhibition of T‐cell localization. In this review, we discuss the current state of CAR T‐cell therapy in solid cancers, the variety of concepts being investigated to overcome these barriers as well as approaches aimed at increasing the specificity and safety of adoptive cell transfer. Abstract : The April 2017 issue of Immunology & Cell Biology contains a Special Feature on Cancer Immunotherapy. This series of reviews highlights some of the recent advances in mobilizing effective host immunity to cancer. Cancer immunotherapy is at a critical and exciting stage of development. Progress in our understanding of cancer immunotherapy has been dramatic over recent years and we have selected six articles to highlight in this Special Feature. The Special Feature begins with an overview of the approaches to targeting inflammation in the cancer microenvironment and follows with a focus of extracellular adenosine as a major immunosuppressive metabolite in tumours. Two subsequent articles detail advances in antibody engineering for engaging the ideal effector responses in tumours and the Special Feature finishes with two articles that explore new approaches in adoptive cellular therapy targeted at tumor and virus specific antigens in tumors. Immunology & C ell Biology thanks the coordinator of this Special Feature ‐ Mark Smyth ‐ for his planning and input.